Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis (Ranibizumab) is effective for macular edema associated with central retinal vein occlusion (CRVO). However, there is little information on whether there are any predictive factors of treatment outcome after this treatment. We plan to perform comprehensive functional and imaging tests to determine significant predictive factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

NCT01028248

Central Retinal Vein Occlusion

COMPLETED PHASE1

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

NCT00403039

Retinal Vein Occlusion

COMPLETED PHASE1

A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

NCT00567697

Central Retinal Vein Occlusion Macular Edema

COMPLETED PHASE3

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

NCT00942864

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE3

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the present study is to investigate predictive factors of treatment outcome after intravitreal injection of Lucentis (Ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO) using various comprehensive clinical tests including visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, new flicker electroretinogram (ERG) using skin electrodes. Corrected visual acuity, visual filed, spectral-domain optical coherence tomography (SD-OCT), ultra wide-field fluorescein angiography, and new flicker electroretinogram (ERG) using skin electrodes are performed before and 3, 6, 9, 12 months after the treatment. Predictive factors of treatment outcome are statistically analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Retinal Vein Occlusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravitreal injection of Ranibizumab

Group Type EXPERIMENTAL

Ranibizumab

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ranibizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Macular edema associated with central retinal vein occlusion
* Best corrected visual acuity \< 20/30
* Central macular thickness \> 300
* Period from symptom onset to treatment \< 12 months